Purpose: Recent real-world studies have demonstrated that asthma control remains suboptimal in many patients. The aim of this study was to evaluate physicians' perceptions of the effectiveness of combination therapy with an inhaled corticosteroid (ICS) and a long-acting β 2 -agonist (LABA) in routine clinical practice. Methods: In November 2009, UK respiratory specialists were invited by medeConnect Healthcare Insight to complete a survey on the effectiveness of different single-or dual-inhaler combinations of an ICS and a LABA in the context of asthma management. Respondents were permitted to specify combinations of available ICSs and LABAs, based on their knowledge and experience of the individual components. Questions elicited both unprompted free-text responses and prompted responses selected from a list of options. Results: A total of 98 physicians completed the survey, of whom 82 (84%) gave permission to publish their data. The majority of respondents (63%) were consultants and 57% reported a caseload of more than 40 patients with asthma or chronic obstructive pulmonary disease per month. Fluticasone and formoterol were considered to be the most effective combination for the treatment of asthma (37% unprompted, 41% prompted), followed by budesonide and formoterol (22% unprompted, 24% prompted). The most common reasons for choosing specific combinations were: rapid onset of action (60%), high potency of the ICS (39%), efficacy (15%), experience of prescribing (13%), clinical evidence (12%), and long-lasting effect (10%). Key properties of the preferred fluticasone and formoterol combination were rapid onset of action and high potency of the ICS (79% for both).
Introduction
Inhaled corticosteroids (ICSs) are the cornerstone of asthma management. National and international guidelines recommend combination therapy with an ICS and a longacting β 2 -agonist (LABA) as the first step-up option for adults and children aged 5 years and over whose asthma is not controlled by low-dose ICS monotherapy. 1−3 Data from robust clinical trials have shown that currently available ICS and LABA combinations are effective in the management of asthma; 4−9 however, recent real-world studies have
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Thomas et al demonstrated that asthma control often remains suboptimal in terms of both acute symptom relief and reduction in the risk of future exacerbations 10, 11 even in those receiving treatment, 12, 13 and this may not be immediately apparent to physicians and patients.
It is unclear whether or not the ICS and LABA combinations that show similar efficacy in clinical trials have equivalent effectiveness in real-world practice. This study set out to evaluate physician perceptions of the effectiveness of combinations of currently available ICSs and LABAs for the management of asthma in routine clinical practice.
Methods
In November 2009, UK respiratory specialists (defined as hospital specialists with a minimum of 5 years' experience who were seeing at least 20 patients with asthma or chronic obstructive pulmonary disease [COPD] per month) were invited to complete an online survey on the effectiveness of different combinations of an ICS and a LABA. Physicians were recruited by medeConnect Healthcare Insight via Doctors.net.uk, the largest online network of medical professionals in the UK.
In the context of a questionnaire about the management of asthma, respondents were asked a series of questions to establish which single-inhaler (fixed) or dualinhaler (free) combination of an ICS and a LABA they considered to be the most effective treatment (see Supplementary information). Each question was asked twice: the first time (unprompted), the respondent provided free-text responses to open-ended questions, and the second time (prompted), the respondent selected their response to a closed question from a list of options. Unprompted (recall) questions avoid priming of responses through free-text answers, but may have limitations of under-reporting because of respondents' memory; surveys using prompted (recognition) questions tend to find higher levels of knowledge than those using an unprompted format but risk seeding answers in respondents' minds. 14, 15 For the unprompted response, any text could be entered. For the prompted responses, participants could choose between the following single-inhaler or dualinhaler combinations of an ICS and a LABA: fluticasone and formoterol, fluticasone and salmeterol, budesonide and formoterol, budesonide and salmeterol, beclometasone and formoterol, and beclometasone and salmeterol. There was also the option of "Other", to allow participants to specify any unlisted combination that they believed was likely to be the most effective. Respondents were permitted to state available and hypothetical single-inhaler or dual-inhaler combinations, based on their knowledge and experience of the individual components.
Before analysis, unprompted responses were grouped either by generic drug name (for answers about the most effective ICS and LABA combination) or by theme (for answers regarding the reasons for a particular choice). Representativeness was assessed in relation to National Health Service Workforce data on medical and dental staff by specialty and grade in 2009 in England 16 and Wales. 17 Detailed information on workforce characteristics was only available for England.
Results

Demographic and clinical characteristics
Of the 98 respondents, 82 (84%) gave permission for their data to be included in the analysis, all of whom answered both the unprompted and prompted questions. Almost threequarters of the participants (73%) were aged 31-40 years. Most (63%) were consultants and the majority (57%) reported having a caseload of more than 40 patients with asthma or COPD per month (see Table 1 ). Overall, 83% of respondents were from England, 9% from Scotland, 6% from Northern Ireland, and 2% from Wales. Job grade, sex, and geographical distribution of English respondents were similar to those of all consultants, associate specialists, staff grades, and registrars in respir atory medicine in England, although specialist registrars, and staff in the Yorkshire and Humber region, were slightly overrepresented (Table 1) . Of all consultants, associate specialists, staff grades and registrars in respiratory medicine, we surveyed approximately 5% (68/1358) in England and 3% (2/59) in Wales.
Most effective iCS and LABA combinations
Respondents considered that the most effective combinations (irrespective of their current availability as single-inhaler or dual-inhaler combinations) would be fluticasone and formoterol (37% unprompted, 41% prompted), followed by budesonide and formoterol (22% unprompted, 24% prompted) (Figure 1) .
When analyzing the components individually, the ICS considered to be most effective was fluticasone (44% unprompted, 49% prompted), followed by budesonide (22% unprompted, 26% prompted), and beclometasone (17% unprompted, 22% prompted) (Figure 2A ). The most effective LABA was thought to be formoterol
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Physician attitudes to combination therapy in uK specialist care (84% unprompted, 87% prompted), followed by salmeterol (11% unprompted, 12% prompted) ( Figure 2B ).
Reasons for iCS and LABA choice
The most common reasons that respondents gave for choosing the ICS and LABA combination they considered to be most effective were: rapid onset of action (60%), high potency of the ICS (39%), efficacy (15%), experience of prescribing (13%), clinical evidence (12%), and long-lasting effect (10%) ( Figure 3A) . The most common reasons given for selecting fluticasone and formoterol (the combination most often rated as being most effective) were rapid onset of action (79%) and high potency of the ICS (79%) ( Figure 3B ).
Discussion
This study aimed to gain an insight into the opinions of UK physicians regarding the effectiveness of different single-inhaler or dual-inhaler combinations of an ICS and a LABA for the treatment of asthma. Using both unprompted and prompted questions, 14, 15 this survey revealed that the 
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Thomas et al preferred choice of UK-based respiratory specialists to optimize combination therapy (ICS and a LABA) was fluticasone and formoterol, which is currently not available as a single-inhaler combination. This choice was followed by budesonide and formoterol, then beclometasone and formoterol. Our study also suggested that the most important properties of a single-or dual-inhaler combination of an ICS and a LABA are high potency of the ICS and rapid onset of action.
The rating of fluticasone as the most effective ICS in combination therapies for asthma appears to be related to its well-established pharmacological potency. Clinical data show that treatment with fluticasone results in improvements in symptoms and lung function, and reduces the frequency of rescue medication use in adults and children with mild to severe asthma when administered at half the equivalent daily dose of budesonide or beclometasone. 18−20 The rating of formoterol as the most effective LABA probably reflects its rapid onset of action compared with salmeterol. 21, 22 Furthermore, a recent systematic review identi fied a greater improvement in symptoms (reduced frequency of rescue medication use and more symptom-free days) and in lung function in patients treated with formoterol compared with those treated with salmeterol. 19 This study has several strengths and limitations. Although the use of an online survey may have led to response bias, survey participants were broadly representative of the target population of respiratory consultants 
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Physician attitudes to combination therapy in uK specialist care and specialist registrars, in terms of sex and geographical distribution. Participants were asked to give unprompted responses first, and these were consistent with the prompted responses that followed. The fact that some available ICSs and LABAs (eg, ciclesonide and indacaterol [not available in the UK at the time of the survey]) were not included in the list of prompted responses is unlikely to have influenced our results, because they were not mentioned unprompted or (with the exception of two mentions of ciclesonide) in the prompted "Other" category. Specific limitations include data collection from respiratory specialists, rather than from primary care where the majority of asthma management takes place, and by focusing on efficacy, this study did not specifically address the question of safety for ICSs and LABAs. Also, this observational survey was a study of "theoretical preference", and was not designed to capture current prescribing patterns, medication usage, or dosage modifications of current formulations. To do this, a prescribing database would be required.
Finally, data from this study are UK specific and may not be representative of the attitudes of respiratory specialists within the wider community in Europe. However, the results are consistent with a recent pan-European study of ICS-prescribing trends, in which fluticasone was shown to be the most widely prescribed ICS (included in 38% of inhalers prescribed), followed by budesonide and beclometasone. 23 Further similar research would be useful to evaluate physician perceptions of the effectiveness of combinations of currently available ICSs and LABAs for the management of other respiratory diseases, especially COPD, both in the specialist setting and in primary care. 
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